Revance Therapeutics reported $198.36M in Cash and Equivalent for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Abbvie ABBV:US $ 6098M 3648M
Aerie Pharmaceuticals AERI:US $ 56.44M 19.25M
ALKERMES ALKS:US $ 282.56M 54.99M
Bristol Myers Squibb BMY:US $ 12369M 1610M
Cara Therapeutics CARA:US $ 21.36M 7.91M
Coherus Biosciences CHRS:US $ 325.68M 91.52M
Eli Lilly And LLY:US $ 2459.2M 1359.3M
Endo International Ordinary Shares ENDP:US $ 1413.15M 94.05M
Horizon Pharma HZNP:US $ 1643.13M 62.81M
Johnson & Johnson JNJ:US $ 1579M 322M
Merk MRK:US $ 8556M 460M
Neurocrine Biosciences NBIX:US $ 270.2M 70.6M
Pacira Pharmaceuticals PCRX:US $ 226.75M 358.83M
Procter & Gamble PG:US $ 8526M 3018M
Revance Therapeutics RVNC:US $ 198.36M 87.74M
Supernus Pharmaceuticals SUPN:US $ 115.72M 87.72M
Teva Pharmaceutical Industries TEVA:US $ 2175M 10M